In simple terms, Biocon’s game plan is this: look for interesting products to develop from all over the world. There would be companies that have discovered potential biotech drugs, but do not have the ability to develop them into full products. Biocon will develop them into drugs and jointly own the intellectual property. It will also manufacture the product for the Indian market and, if possible, for the entire world. Besides, it could have the marketing rights for India and some other regions. It is a unique business model for a biotech company at the moment.
Arun Natarajan is the Founder of Venture Intelligence India, which tracks venture capital activity in India and Indian-founded companies worldwide. View sample issues of Venture Intelligence India newsletters and reports.